July 24, 2020


WASHINGTON, D.C. – U.S. Chamber of Commerce Executive Vice President and Chief Policy Officer Neil Bradley issued the following statement today after the White House issued Executive Orders on drug pricing:

“While we will review the executive orders carefully, government regulation of contracts, reimportation, and importing foreign price controls are reckless and dangerous policies and the wrong way to try to reduce drug costs. These actions would risk myriad collateral consequences, including higher premiums, diminished drug safety, and a substantial reduction in investment in new cures. We urge the administration to reconsider this approach. A much better approach is to focus on ensuring that other countries bear their fair share of the burden of the significant costs of drug research and development.”